Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience
Open Access
- 9 September 2016
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 16 (1) , 111
Abstract
Gastric neuroendocrine neoplasms (G-NENs) are uncommon, and data on their management is limited. We here investigated the clinicopathological characteristics, surgical and survival outcomes in G-NENs among Chinese. Moreover, we will discuss their prognostic value. From existing databases of the West China Hospital, we retrospectively identified 135 consecutive patients who were surgically treated and pathologically diagnosed as G-NENs from January 2009 to August 2015. This entire cohort comprised 98 males and 37 females, with a median age of 60 years. Twenty-five patients underwent endoscopic resection, while 110 patients underwent open/laparoscopic surgery. Thirty-nine patients had neuroendocrine tumor G1 (NET G1), seven patients had neuroendocrine tumor G2 (NET G2), 69 patients had neuroendocrine carcinoma G3 (NEC G3) and 20 patients had mixed adenoneuroendocrine carcinoma (MANEC). The median survival was not achieved for both NET G1 and NET G2 versus 19 months (range 3–48) for NEC G3 and 10.5 months (range 3–45) for MANEC. The 3-year survival rates for stage I, II, III, and IV were 91.1 %, 78.6 %, 51.1 % and 11.8 %, respectively (P < 0.001). As for the prognostic analysis, both surgical margin and the newly updated World Health Organization (WHO) classification were independent predictors of overall survival (OS). G-NENs are a kind of rare tumors, and patients with NET G3 and MANEC have unfavorable prognosis even surgically treated. Moreover, surgical margin and the new 2010 WHO criteria are closely associated with OS for G-NENs.Keywords
This publication has 32 references indexed in Scilit:
- Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter StudyCancer Research and Treatment, 2012
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Gut, 2011
- Multimodal management of neuroendocrine liver metastasesHPB, 2010
- Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)Annals of Oncology, 2010
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine TumorsAnnals of Surgery, 2008
- Survival From Malignant Digestive Endocrine Tumors in England and Wales: A Population-Based StudyGastroenterology, 2007
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Incidence and management of malignant digestive endocrine tumours in a well defined French populationGut, 2004
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003